Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 11INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2CNS 2Tumor-Agnostic 1Dermatologic 1Breast 1

Conditions

Astrocytoma 2Glioma 1Glioblastoma 1Brain Neoplasms 1

Interventions

Temozolomide 123Radiotherapy 47Bevacizumab 46Lomustine 25Radiation 20Nivolumab 17Irinotecan 16Carboplatin 16Cyclophosphamide 14Granulocyte-Macrophage Colony-Stimulating Factor 13pembrolizumab 11dabrafenib 10Trastuzumab 10Surgical Procedures, Operative 10Capecitabine 10paclitaxel-Angiopep-2 conjugate 8TIC10 compound 8Paclitaxel 8Gemcitabine 8Carmustine 8trametinib 7Topotecan 7IL13-PE38 7Everolimus 7Drug Therapy 7Aminolevulinic Acid 7AZD 6244 73-Iodobenzylguanidine 7fludarabine 6enzastaurin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Eflornithine × CNS × Clear all
NCT05879367 2025-06-25

Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

Orbus Therapeutics, Inc.

Phase 1 Recruiting
66 enrolled
CNS

Astrocytoma, Glioblastoma

NCT02796261 2022-01-21

STELLAR

Orbus Therapeutics, Inc.

Phase 3 Unknown
343 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡